Glueck C J, Glueck H I, Tracy T, Speirs J, McCray C, Stroop D
Cholesterol Center, Jewish Hospital, Cincinnati, OH 45229.
Metabolism. 1993 Feb;42(2):236-46. doi: 10.1016/0026-0495(93)90042-m.
In 191 newly referred hyperlipidemic patients, our specific aim was to assess relationships between levels of lipoprotein(a) [Lp(a)], lipids, apolipoproteins, regulators of basal and stimulated fibrinolytic activity, and D-dimer, a measure of in vivo fibrinolysis. Lp(a) levels correlated with none of the measures of basal fibrinolytic regulators or D-dimer. In 25 patients, levels of stimulated regulators of fibrinolytic activity and D-dimer were measured after 10-minute cuff venous occlusion. Lp(a) levels again correlated with none of the stimulated regulators of fibrinolytic activity or D-dimer. However, both basal and stimulated levels of fibrinolytic regulators and D-dimer were closely related to other major risk factors for coronary heart disease (CHD) including triglyceride, apolipoprotein (apo) A1, apo B, Quetelet index (QI), and sex. By stepwise regression in 191 patients, the following standardized partial regression coefficients were significant (P < or = .05), and model R2 and P values were as follows: basal tissue plasminogen activator (tPA) with apo B-.18, with time .17, with QI -.28, R2 = 17%, P < or = .0001; basal plasminogen activator inhibitor (PAI) with apo B..25, with time -.15, with QI .17, R2 = 14%, P < or = .0001; basal alpha 2-antiplasmin with apo A1.14, with apo B.24, with QI.17, with sex .30, R2 = 25%, P < .0001; basal plasminogen with A1.15, with apo B.21, with QI.17, with sex.17, R2 = 15%, P < or = .0001; basal fibrinogen with Lp(a).17, with QI.21, with sex.26, R2 = 14%, P < or = .0001; D-dimer with sex.15, R2 = 21%, P < or = .048. Given the absence of any relationship between Lp(a) levels and inhibition or stimulation of fibrinolysis regulators or D-dimer either in the basal or stimulated state, we postulate that Lp(a)'s major atherogenic effects are mediated by mechanisms other than reduction of fibrinolysis stimulation or in vivo fibrinolysis.
在191例新转诊的高脂血症患者中,我们的具体目标是评估脂蛋白(a)[Lp(a)]水平、血脂、载脂蛋白、基础和刺激纤溶活性调节剂以及D-二聚体(体内纤溶的一项指标)之间的关系。Lp(a)水平与基础纤溶调节剂或D-二聚体的各项指标均无相关性。在25例患者中,在袖带静脉闭塞10分钟后测量刺激后的纤溶活性调节剂和D-二聚体水平。Lp(a)水平再次与刺激后的纤溶活性调节剂或D-二聚体均无相关性。然而,纤溶调节剂和D-二聚体的基础水平和刺激后水平均与冠心病(CHD)的其他主要危险因素密切相关,包括甘油三酯、载脂蛋白(apo)A1、apo B、体重指数(QI)和性别。通过对191例患者进行逐步回归分析,以下标准化偏回归系数具有显著性(P≤0.05),模型R2和P值如下:基础组织纤溶酶原激活物(tPA)与apo B的偏回归系数为-0.18,与时间的偏回归系数为0.17,与QI的偏回归系数为-0.28,R2 = 17%,P≤0.0001;基础纤溶酶原激活物抑制剂(PAI)与apo B的偏回归系数为0.25,与时间的偏回归系数为-0.15,与QI的偏回归系数为0.17,R2 = 14%,P≤0.0001;基础α2-抗纤溶酶与apo A1的偏回归系数为0.14,与apo B的偏回归系数为0.24,与QI的偏回归系数为0.17,与性别的偏回归系数为0.30,R2 = 25%,P < 0.0001;基础纤溶酶原与apo A1的偏回归系数为0.15,与apo B的偏回归系数为0.21,与QI的偏回归系数为0.17,与性别的偏回归系数为0.17,R2 = 15%,P≤0.0001;基础纤维蛋白原与Lp(a)的偏回归系数为0.17,与QI的偏回归系数为0.21,与性别的偏回归系数为0.26,R2 = 14%,P≤0.0001;D-二聚体与性别的偏回归系数为0.15,R2 = 21%,P≤0.048。鉴于在基础或刺激状态下Lp(a)水平与纤溶调节剂或D-二聚体的抑制或刺激之间均不存在任何关系,我们推测Lp(a)的主要致动脉粥样硬化作用是由纤溶刺激降低或体内纤溶以外的机制介导的。